Carlos Lumbreras Bermejo-rekin lankidetzan egindako argitalpenak (8)

2023

  1. Mortality reduction in older COVID-19-patients hospitalized in Spain during the second pandemic wave from the SEMI-COVID-19 Registry

    Scientific Reports, Vol. 13, Núm. 1

2022

  1. Remdesivir in Very Old Patients (≥80 Years) Hospitalized with COVID-19: Real World Data from the SEMI-COVID-19 Registry

    Journal of Clinical Medicine, Vol. 11, Núm. 13

2006

  1. Randomized study of cefepime versus ceftazidime plus amikacin in patients with solid tumors treated with high dose chemotherapy (HDC) and peripheral blood stem cell support (PBSCS) with febrile neutropenia

    Clinical and Translational Oncology, Vol. 8, Núm. 12, pp. 889-895

2001

  1. Granulocyte colony-stimulating factor in the treatment of high-risk febrile neutropenia: A multicenter randomized trial

    Journal of the National Cancer Institute, Vol. 93, Núm. 1, pp. 31-38

2000

  1. Rifampin does not improve the efficacy of quinolone antibacterial prophylaxis in neutropenic cancer patients: Results of a randomized clinical trial

    Journal of Clinical Oncology, Vol. 18, Núm. 10, pp. 2126-2134

1999

  1. Incidence and clinical impact of fluoroquinolone-resistant Escherichia coli in the faecal flora of cancer patients treated with high dose chemotherapy and ciprofloxacin prophylaxis

    Journal of Antimicrobial Chemotherapy, Vol. 44, Núm. 1, pp. 117-120

  2. Outpatient therapy with oral ofloxacin for patients with low risk neutropenia and fever: A prospective, randomized clinical trial

    Cancer, Vol. 85, Núm. 1, pp. 213-219

1997

  1. Lack of ability of ciprofloxacin-rifampin prophylaxis to decrease infection-related morbidity in neutropenic patients given cytotoxic therapy and peripheral blood stem cell transplants

    Antimicrobial Agents and Chemotherapy, Vol. 41, Núm. 5, pp. 1175-1177